Funding for Alzheimer's drug development from pre-clinical to Phase I clinical trials to prevent, slow, or treat AD symptoms, excluding basic research and non-pharmacological interventions.
Drug Development RFP supports researchers and clinicians developing drugs and devices through IND-enabling studies and early clinical trials to advance treatments for Alzheimer’s disease and related dementias.
This grant supports combined Phase 1/2a clinical trials testing new drugs (excluding amyloid/tau targets) for Alzheimer's, using a milestone-driven approach.
This grant supports research to optimize and advance genomic and biologic therapies for Alzheimer’s-related dementias, from preclinical development through early clinical evaluation.
The NIA will fund programs giving recent college graduates intensive research experience in Alzheimer's and related dementias to prepare them for advanced study or research careers.